{
    "title": "112_hr4087",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Prescription Drug Labeling Promotion \nAct of 2012''.\n\nSEC. 2. ACCESSIBILITY OF INFORMATION IN PRESCRIPTION DRUG LABELING BY \n              VISUALLY-IMPAIRED AND BLIND CONSUMERS.\n\n    (a) Establishment of Working Group.--\n            (1) In general.--The Secretary of Health and Human Services \n        (in this section referred to as the ``Secretary'') shall \n        establish a working group (in this section referred to as the \n        ``working group'') to develop and promulgate guidance \n        constituting best practices on access to prescription drug \n        labeling for the visually impaired.\n            (2) Members.--The working group shall include \n        representatives of national organizations representing blind \n        and visually impaired individuals, national organizations \n        representing the elderly, and industry groups representing \n        stakeholders, including pharmacists, who would be impacted by \n        such best practices. Representation within the working group \n        shall be divided equally between consumer and industry \n        advocates.\n            (3) Guidance on best practices.--The working group shall \n        promulgate, not later than 1 year after the date of the \n        enactment of this Act, guidance on best practices for \n        pharmacies to ensure that blind and visually impaired \n        individuals have safe, consistent, reliable, and independent \n        access to the information in the labeling of prescription \n        drugs. Such guidance shall be made available through \n        publication in the Federal Register and posting on the Web site \n        of the Food and Drug Administration.\n            (4) Considerations.--In developing and promulgating such \n        guidance on best practices, the working group shall consider--\n                    (A) the use of--\n                            (i) Braille;\n                            (ii) auditory means, such as--\n                                    (I) ``talking bottles'' that \n                                provide audible label information;\n                                    (II) digital voice recorders \n                                attached to the prescription drug \n                                container; and\n                                    (III) radio frequency \n                                identification (RFID) tags; and\n                            (iii) enhanced visual means, such as--\n                                    (I) large font labels or large font \n                                ``duplicate'' labels that are affixed \n                                or matched to a prescription drug \n                                container;\n                                    (II) high-contrast printing; and\n                                    (III) sans-serf font;\n                    (B) whether there are technical, financial, \n                manpower, or other factors unique to pharmacies with 20 \n                or fewer retail locations which may fundamentally \n                impact the ability of such pharmacies to implement the \n                best practices; and\n                    (C) such other factors as the working group \n                determines to be appropriate.\n            (5) Information campaign.--Upon the promulgation of the \n        guidance on best practices, the Commissioner of Food and Drugs, \n        in consultation with the working group, shall conduct an \n        informational and educational program designed to inform the \n        public and pharmacists about such guidance and practices.\n            (6) FACA waiver.--The Federal Advisory Committee Act shall \n        not apply to the working group.\n    (b) GAO Study.--\n            (1) In general.--Beginning 18 months after the publication \n        of the guidance on best practices under subsection (a), the \n        Comptroller General of the United States shall conduct a review \n        of such guidance, the extent to which pharmacies are complying \n        with such best practices, and the extent to which barriers to \n        accessible prescription drug labeling for blind and visually-\n        impaired individuals continue.\n            (2) Report.--Not later than September 30, 2016, the \n        Comptroller General shall submit to Congress a report on the \n        review conducted under paragraph (1). Such report shall include \n        recommendations for how best to reduce the barriers blind and \n        visually-impaired individuals have to access prescription drug \n        labeling.\n    (c) Definitions.--In this section:\n            (1) The term ``pharmacy'' includes a pharmacy that receives \n        prescriptions, and dispenses prescription drugs, through an \n        Internet Web site.\n            (2) The term ``prescription drug'' means a drug subject to \n        section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act \n        (21 U.S.C. 353(b)(1))."
}